HomeInsightsStock Comparison

Gland Pharma Ltd vs Natco Pharma Ltd Stock Comparison

Gland Pharma Ltd vs Natco Pharma Ltd Stock Comparison

Last Updated on: Jun 02, 2025

Key Highlights

  • The Latest Trading Price of Gland Pharma Ltd is ₹ 1609 as of 02 Jun 16:01.
  • The P/E Ratio of Gland Pharma Ltd changed from 40.7 on March 2021 to 39.3 on March 2024 . This represents a CAGR of -0.87% over 4 yearsThe P/E Ratio of Natco Pharma Ltd changed from 20 on March 2020 to 12.3 on March 2024 . This represents a CAGR of -9.26% over 5 years.
  • The Market Cap of Gland Pharma Ltd changed from ₹ 40535 crore on March 2021 to ₹ 30338 crore on March 2024 . This represents a CAGR of -6.99% over 4 yearsThe Market Cap of Natco Pharma Ltd changed from ₹ 9215 crore on March 2020 to ₹ 17042 crore on March 2024 . This represents a CAGR of 13.08% over 5 years.
  • The revenue of Gland Pharma Ltd for the Mar '25 is ₹ 1468 crore as compare to the Dec '24 revenue of ₹ 1442 crore. This represent the growth of 1.83% The revenue of Natco Pharma Ltd for the Mar '25 is ₹ 1287 crore as compare to the Dec '24 revenue of ₹ 651.1 crore. This represent the growth of 97.71%.
  • The ebitda of Gland Pharma Ltd for the Mar '25 is ₹ 391.54 crore as compare to the Dec '24 ebitda of ₹ 418.45 crore. This represent the decline of -6.43% The ebitda of Natco Pharma Ltd for the Mar '25 is ₹ 614.4 crore as compare to the Dec '24 ebitda of ₹ 215.1 crore. This represent the growth of 185.63%.
  • The net profit of Gland Pharma Ltd changed from ₹ 194.1 crore to ₹ 186.54 crore over 8 quarters. This represents a CAGR of -1.97% The net profit of Natco Pharma Ltd changed from ₹ 420.3 crore to ₹ 406 crore over 8 quarters. This represents a CAGR of -1.72% .
  • The Dividend Payout of Gland Pharma Ltd changed from 31.57 % on March 2024 to 31.57 % on March 2024 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Natco Pharma Ltd changed from 25.89 % on March 2020 to 13.01 % on March 2024 . This represents a CAGR of -12.86% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Gland Pharma Ltd

  • Gland Pharma Limited was incorporated as Gland Pharma Private Limited', a private limited company on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad.
  • Subsequently, the name of the Company was changed to Gland Pharma Limited' and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.
  • The Company is primarily engaged in manufacturing injectable formulations. The company is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019.
  • The company has 8 manufacturing facilities in India, comprising four finished formulations facilities with a total of 23 production lines and three API facilities.

About Natco Pharma Ltd

  • Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
  • The Company's focus is primarily on niche therapeutic areas and complex products.
  • It sells products in over 40 countries.
  • FDF products are sold in the United States, India, Europe and the rest of the world (RoW).
  • Natco's API products are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. Natco Pharma is also engaged in contract manufacturing business, whereby the company undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.

Gland Pharma Ltd News Hub

News

Gland Pharma to hold AGM

Gland Pharma announced that the Annual General Meeting(AGM) of the company will be held on...

Read more

21 May 2025 15:23

News

Board of Gland Pharma recommends final dividend

Gland Pharma announced that the Board of Directors of the Company at its meeting held on 2...

Read more

20 May 2025 21:08

News

Gland Pharma announces board meeting date

Gland Pharma will hold a meeting of the Board of Directors of the Company on 20 May 2025. ...

Read more

07 May 2025 11:32

News

Gland Pharma receives USFDA approval for Latanoprostene Bunod Ophthalmic Solution

Gland Pharma has received approval from the United States Food and Drug Administration (US...

Read more

30 Apr 2025 14:20

News

Gland Pharma receives USFDA approval for Acetaminophen Injection 10 mg/mL

Gland Pharma has received approval from the United States Food and Drug Administration (US...

Read more

03 Apr 2025 11:22

News

Gland Pharma Ltd Spurts 9.65%, BSE Healthcare index Gains 2.92%

Gland Pharma Ltd gained 9.65% today to trade at Rs 1683.25. The BSE Healthcare index is up...

Read more

03 Apr 2025 09:30

Natco Pharma Ltd News Hub

News

Natco Pharma gains after Q4 PAT rises 5% YoY to Rs 407 cr

Profit before tax (PBT) increased 5.9% YoY to Rs 505.90 crore in the quarter ended 31st Ma...

Read more

29 May 2025 15:50

News

Natco Pharma to conduct board meeting

Natco Pharma will hold a meeting of the Board of Directors of the Company on 28 May 2025. ...

Read more

13 May 2025 10:19

News

Natco Pharma update on launch of Risdiplam in India

Natco Pharma today updates on the legal proceedings on Risdiplam launch in India. The Comp...

Read more

08 Apr 2025 11:16

News

Natco Pharma Ltd up for fifth session

Natco Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 8...

Read more

07 Mar 2025 13:00

News

Natco Pharma Ltd soars 1.69%

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 837...

Read more

25 Feb 2025 13:05

News

Natco Pharma slips as Q3 PAT slides 38% YoY to Rs 132 cr

Profit before tax in Q3 FY25 stood at Rs 163.7 crore, down 36.13% as against Rs 256.3 cror...

Read more

13 Feb 2025 11:11

SWOT Analysis Of Gland Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Gland Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Gland Pharma Ltd and Natco Pharma Ltd

Which company has a larger market capitalization, Gland Pharma Ltd or Natco Pharma Ltd?

Market cap of Gland Pharma Ltd is 26,169 Cr while Market cap of Natco Pharma Ltd is 15,823 Cr

What are the key factors driving the stock performance of Gland Pharma Ltd and Natco Pharma Ltd?

The stock performance of Gland Pharma Ltd and Natco Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gland Pharma Ltd and Natco Pharma Ltd?

As of June 2, 2025, the Gland Pharma Ltd stock price is INR ₹1588.35. On the other hand, Natco Pharma Ltd stock price is INR ₹883.45.

How do dividend payouts of Gland Pharma Ltd and Natco Pharma Ltd compare?

To compare the dividend payouts of Gland Pharma Ltd and Natco Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions